Skip to main content

A Case Study for Adaptive Trial Design Consideration and Implementation

  • Chapter
  • First Online:
  • 2071 Accesses

Part of the book series: Statistics for Biology and Health ((SBH))

Abstract

The use of adaptive designs in dose ranging studies can increase the efficiency of drug development by improving our ability to efficiently learn about the dose–response and better determine whether to take a drug forward into confirmatory phase testing and at what dose. This approach can maximize the ability to test a larger number of doses in a single trial while simultaneously increasing the efficiency of the trial in terms of making better go–no-go decisions about continuing the trial and/or the development of the drug for a specific indication.

We show in a real case study of a dose ranging trial in patients with acute exacerbations of schizophrenia how such an adaptive design explicitly addresses multiple trial goals, adaptively allocates subjects according to ongoing information needs, and allows termination for both early success and futility.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Antonijevic Z, Gallo P, Chuang-Stein C, Dragalin V, Loewy J, Menon S, Miller E, Morgan CC, Sanchez M (2013) Views on emerging issues pertaining to data monitoring committees for adaptive trials. Drug Inf J 47:495–502

    Google Scholar 

  • Berry D (2004) Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 19:175–187

    Article  MATH  Google Scholar 

  • Berry D, Muller P, Grieve AP, Smith MK, Parke T, Blazek R, Mitchard N, Krams M (2002) Adaptive Bayesian designs for dose-ranging trials. In: Carlin B, Carriquiry A, Gatsonis C, Gelman A, Kass RE, Verdinelli I, West M (eds) Case studies in Bayesian statistics V. Springer, Berlin, pp 99–181

    Chapter  Google Scholar 

  • Dragalin V (2006) Adaptive designs: terminology and classification. Drug Inf J 40:425–435

    Google Scholar 

  • Fardipour P, Littman G, Burns DD, Dragalin V, Padmanabhan SK, Parke T et al (2009a) Planning and executing response-adaptive learn-phase clinical trials: 1. The process. Drug Inf J 43:713–723

    Article  Google Scholar 

  • Fardipour P, Littman G, Burns DD, Dragalin V, Padmanabhan SK, Parke T et al (2009b) Planning and executing response-adaptive learn-phase clinical trials: 2. Case studies. Drug Inf J 43:725–734

    Article  Google Scholar 

  • Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J et al (2006) Adaptive designs in clinical drug development – an executive summary of the PhRMA working Group. J Biopharm Stat 16(3):275–283, Discussion 285–291, 293–278, 311–272

    Article  MathSciNet  Google Scholar 

  • Krams M, Sharma A, Dragalin V, Burns D, Fardipour P, Padmanabhan SK et al (2009) Adaptive approaches in drug development. Opportunities and challenges in design and implementation. Pharm Med 23:139–148

    Google Scholar 

  • Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Golub H, Evers M, Fleming E, Singh N, Tramontin T (2009) The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 8:1–9

    Article  Google Scholar 

  • Padmanabhan SK, Berry S, Dragalin V, Krams M (2012) A Bayesian dose-finding design adapting to efficacy and tolerability response. J Biopharm Stat 22:276–293

    Article  MathSciNet  Google Scholar 

  • Shen J, Preskorn S, Dragalin V, Slomkowski M, Padmanabhan SK, Fardipour P, Sharma A, Krams M (2011) How adaptive trial designs can increase efficiency in psychiatric drug development: a case study. Innov Clin Neurosci 8(26):26–34

    Google Scholar 

  • Smith M, Jones I, Morris M, Grieve A, Tan K (2006) Implementation of a Bayesian adaptive design in a proof of concept study. Pharm Stat 5:39–50

    Article  Google Scholar 

  • Thall PF, Wathen JK (2007) Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 43:859–866

    Article  Google Scholar 

  • West M, Harrison J (1997) Bayesian forecasting and dynamic models, 2nd edn. Springer-Verlag, New York

    MATH  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vladimir Dragalin .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dragalin, V., Krams, M. (2014). A Case Study for Adaptive Trial Design Consideration and Implementation. In: He, W., Pinheiro, J., Kuznetsova, O. (eds) Practical Considerations for Adaptive Trial Design and Implementation. Statistics for Biology and Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1100-4_17

Download citation

Publish with us

Policies and ethics